-+ 0.00%
-+ 0.00%
-+ 0.00%

Simcere Wins German Approval for Phase 1 Trial of SIM0709

PUBT·11/09/2026 08:50:59
Listen to the news
Simcere Wins German Approval for Phase 1 Trial of SIM0709
  • Simcere Pharmaceutical received German regulatory and ethics clearance to begin a Phase 1 trial of SIM0709 in healthy participants.
  • The bispecific antibody targets inflammatory bowel disease and is being developed globally with Boehringer Ingelheim.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12405386), on November 09, 2026, and is solely responsible for the information contained therein.